Stemline Therapeutics Inc (NASDAQ:STML) shares fell 5.7% on Friday . The company traded as low as $13.19 and last traded at $13.21, 577,515 shares traded hands during trading. A decline of 5% from the average session volume of 605,249 shares. The stock had previously closed at $14.01.
A number of research firms have recently weighed in on STML. Piper Jaffray Companies set a $75.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, March 18th. Wedbush reaffirmed a “buy” rating and set a $95.00 price target on shares of Global Blood Therapeutics in a research note on Monday, May 13th. Roth Capital reaffirmed a “buy” rating on shares of Resverlogix in a research note on Thursday, May 23rd. ValuEngine raised Vermillion from a “hold” rating to a “buy” rating in a research note on Wednesday, May 15th. Finally, BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 4th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Stemline Therapeutics has an average rating of “Buy” and a consensus target price of $25.20.
The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The company’s fifty day moving average price is $14.46.
Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analyst estimates of $2.61 million. Equities research analysts anticipate that Stemline Therapeutics Inc will post -2.14 earnings per share for the current year.
In other news, CEO Ivan Bergstein sold 56,316 shares of the stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $15.08, for a total transaction of $849,245.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Kenneth Hoberman sold 9,107 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total value of $141,067.43. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,177 shares of company stock worth $2,236,377. 13.10% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA acquired a new stake in Stemline Therapeutics in the 1st quarter valued at approximately $102,000. Knott David M grew its holdings in Stemline Therapeutics by 1.3% in the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares during the last quarter. Legal & General Group Plc grew its holdings in Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares during the last quarter. Bank of America Corp DE grew its holdings in Stemline Therapeutics by 56.8% in the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,866 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Stemline Therapeutics by 26.5% in the 4th quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 28,198 shares during the last quarter. 77.66% of the stock is currently owned by hedge funds and other institutional investors.
About Stemline Therapeutics (NASDAQ:STML)
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.